Email
IAC Express #1,541 - Your weekly immunization news service: Second COVID-19 vaccine EUA issued, ACIP recommends vaccine, new resources, and more
| From | Immunization Action Coalition <[email protected]> |
| Subject | IAC Express #1,541 - Your weekly immunization news service: Second COVID-19 vaccine EUA issued, ACIP recommends vaccine, new resources, and more |
| Date | December 23, 2020 1:28 PM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,541: December 23, 2020
Top Stories
* Happy holidays from all of us at IAC! We'll be back on January 6, 2021
* FDA issues EUA for Moderna mRNA vaccine after advisory committee vote; fact sheets published
* ACIP recommends second COVID-19 vaccine for use in U.S.; IAC summarizes December 19 meeting and highlights clinical considerations for use of mRNA vaccines
* ACIP provides interim recommendation for people who will be in Phases 1b and 1c of COVID-19 vaccination priority groups in the United States
* CDC updates web pages featuring practical materials for administration, storage, and handling of each authorized COVID-19 vaccine
* MMWR Recap: CDC publishes recommendations for COVID-19 vaccines and phased allocation: Moderna’s vaccine in December 20 Early Release and Pfizer-BioTech’s vaccine on December 18
* CDC adds many more ready-to-use materials to its COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians
* Becker's Hospital Review publishes "Influenza Vaccination Remains a Priority Even as We Begin Rolling Out a COVID-19 Vaccination Program" by IAC authors—find it on IAC’s mass-vaccination-resources.org website
* Voices for Vaccines releases new podcast, "Dr. Offit Talks COVID-19 Vaccines," with answers to common COVID-19 questions
* HRSA announces competition, with up to 70 cash prizes totaling $1 million, to address declining vaccination coverage and well-child visits
* IAC experts called on by news media
* Not-to-miss immunization articles in the news
Featured Resources
* In IAC’s “Video of the Week,” the Alliance for Aging Research acknowledges pandemic stress and the importance of getting vaccinated against COVID-19
Journal Articles and Newsletters
* CHOP's Vaccine Education Center publishes December issue of Vaccine Update newsletter
On the Lighter Side
* Watch this vintage PSA about IAC Express from 2006, created by CDC and aired many times on CDC’s “Immunization Update” satellite broadcasts
------------------------------------------------------------
Top Stories
------------------------------------------------------------
HAPPY HOLIDAYS FROM ALL OF US AT IAC! WE'LL BE BACK ON JANUARY 6, 2021
All of us at the Immunization Action Coalition (IAC) wish you, our readers, a safe, happy, and healthy remainder of the holiday season. We do not plan to publish another issue of IAC Express until January 6, 2021. But we will stay alert in these turbulent times and will publish a special edition, if warranted.
The IAC office will be closed on December 24 and 25, as well as January 1.
Happy holidays!
Group photo taken pre-pandemic in February 2020.
------------------------------------------------------------
FDA ISSUES EUA FOR MODERNA MRNA VACCINE AFTER ADVISORY COMMITTEE VOTE; FACT SHEETS PUBLISHED
On December 18, the Food and Drug Administration (FDA) issued the second Emergency Use Authorization ([link removed]) (EUA) for a vaccine to help prevent COVID-19 caused by SARS-CoV-2 virus in people 18 years of age and older. The EUA allows the Moderna COVID-19 vaccine (also known as mRNA-1273) to be distributed in the United States.
FDA’s action aligns with the unanimous recommendation of its Vaccines and Related Biological Products Advisory Committee ([link removed]) (VRBPAC), which determined on December 17 that the totality of scientific evidence available to date indicates that the benefits of vaccination with the Moderna COVID-19 vaccine outweigh the risks for use in people 18 years or older.
Below appear links to technical and supportive documents related to Moderna’s vaccine and the EUA. Most relevant to vaccinators are the Fact Sheet for Potential Recipients and Caregivers ([link removed]) and the Fact Sheet for Vaccination Providers ([link removed]). That second 22-page document contains 7 pages of EUA information plus 15 pages of the product’s prescribing information.
Related Links
* FDA's Press Release: FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine ([link removed]) (12/18/20)
* Moderna COVID-19 Vaccine EUA Fact Sheet for Potential Recipients and Caregivers ([link removed]) (5 pages)
* Moderna COVID-19 Vaccine EUA Fact Sheet for Vaccination Providers ([link removed]) (22 pages)
* FDA’s Letter to Moderna Issuing EUA ([link removed])
* FDA’s COVID-19 Vaccines ([link removed]) gateway page
* FDA’s Emergency Use Authorization for Vaccines Explained ([link removed]) web page
* FDA’s documents from December 17 VRBPAC meeting ([link removed])
* FDA’s Vaccine Development 101 ([link removed])
* FDA's Vaccine Facts: The Path for a COVID-19 Vaccine from Research to EUA ([link removed])
* Examples of Moderna COVID-19 Vaccine package labeling ([link removed])
------------------------------------------------------------
ACIP RECOMMENDS SECOND COVID-19 VACCINE FOR USE IN U.S.; IAC SUMMARIZES DECEMBER 19 MEETING AND HIGHLIGHTS CLINICAL CONSIDERATIONS FOR USE OF MRNA VACCINES
On December 19 ([link removed]), the Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of the Moderna COVID-19 vaccine for persons 18 years of age and older in the United States. This vote followed issuance of the FDA’s Emergency Use Authorization ([link removed]) (EUA) for the vaccine on December 18 (see story above).
The ACIP recommendations and additional guidance for the vaccine’s use became official when they were adopted by CDC and published as ACIP’s Interim Recommendation for Use of Moderna COVID-19 Vaccine—U.S, December 2020 ([link removed]) in the Morbidity and Mortality Weekly Report (MMWR) Early Release issued on December 20 ([link removed]).
Prior to the vote, ACIP received an overview of the mRNA-1273 vaccine from Moderna representatives. The Committee also reviewed its Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach and assessed available vaccine information using its Evidence to Recommendation (EtR) framework.
ACIP also received an update on anaphylaxis incidents following receipt of the Pfizer-BioNTech mRNA vaccine in the United Kingdom and the United States. All cases occurred within several minutes and were promptly treated. The prescribing information for both the Pfizer-BioNTech and Moderna COVID-19 vaccines states that a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine is a contraindication to vaccination. While these anaphylactic occurrences have been rare, all vaccination sites should be prepared to respond appropriately. CDC has posted Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites ([link removed]) to assist facilities in being prepared to recognize, respond, and report anaphylaxis. The guidance recommends that persons with a history of anaphylaxis (due to any cause) be observed for 30 minutes following vaccination. The recommended observation period for other persons is 15 minutes. Vaccination sites should prioritize the training of staff to recognize the early signs of anaphylaxis. Clinic personnel may refer to the CDC guidance for details about preparation for, assessment, and management of anaphylaxis.
CDC has posted Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States ([link removed]). Because the Pfizer-BioNTech and Moderna COVID-19 vaccines are both based on a mRNA platform, the clinical considerations for both vaccines are similar and have been incorporated on a single web page. Where appropriate, the page also notes the differences in the clinical considerations for the two vaccines. Consult the full web page for important details in vaccine administration with either vaccine. The key differences between the two products are highlighted below.
* Authorized age groups (under the Emergency Use Authorizations [EUAs])
+ Pfizer-BioNTech: ages 16 years and older
+ Moderna: ages 18 years and older
* Administration: The mRNA COVID-19 vaccine series consists of two doses administered intramuscularly:
+ Pfizer-BioNTech (30 µg, 0.3 ml): three weeks (21 days) apart*
+ Moderna (100 µg, 0.5 ml): one month (28 days) apart*
*Second doses administered within a grace period of no more than 4 days from the recommended date for the second dose are considered valid. However, doses administered earlier do not need to be repeated. The second dose should be administered as close to the recommended interval as possible. However, there is no maximum interval between the first and second dose for either vaccine. Do not restart the vaccination series.
* Interchangeability of COVID-19 vaccine products: ACIP did not state a preference for use of either mRNA vaccine. But the vaccines are NOT interchangeable, and care should be taken to ensure the same vaccine is used for both doses. However, if different mRNA vaccines are inadvertently administered, no additional doses of either vaccine are recommended at this time.
CDC is updating the COVID-19 information on its web pages frequently, with several key resources listed below.
Related Links
* ACIP Presentation Slides: December 19–20, 2020 ([link removed]) meeting gateway page
* MMWR: ACIP’s Interim Recommendation for Use of Moderna COVID-19—U.S, December 2020 ([link removed] )
* CDC’s Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites ([link removed])
* CDC’s Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States ([link removed])
* CDC’s COVID-19 Vaccination ([link removed]) gateway page for healthcare professionals
* CDC's COVID-19 Vaccine Information for the Public ([link removed]) gateway page
* Moderna’s Fact Sheet for Vaccination Providers ([link removed]) (PDF)
* Moderna’s Fact Sheet for Recipients and Caregivers ([link removed]) (PDF)
------------------------------------------------------------
ACIP PROVIDES INTERIM RECOMMENDATION FOR PEOPLE WHO WILL BE IN PHASES 1B AND 1C OF COVID-19 VACCINATION PRIORITY GROUPS IN THE UNITED STATES
During its meeting on December 20, the Advisory Committee on Immunization Practices (ACIP) approved a recommendation designating persons to include in Phases 1b and 1c of COVID-19 vaccination efforts during times of limited vaccine availability. This decision was an update to ACIP’s previous recommendation to include healthcare workers and residents of long-term care facilities in Phase 1a ([link removed]).
Specifically, the interim recommendation includes the following populations:
* Phase 1b: persons age 75 years and older and frontline essential workers*
* Phase 1c: persons age 65–74 years, persons age 16–64 years with high-risk medical conditions, and other essential workers*
* “Frontline essential workers” include workers who are in sectors essential to the functioning of society and who are at substantially higher risk for exposure to SARS-CoV-2 virus. Occupations in this group include first responders (e.g., firefighters, police), education staff (e.g., teachers, support staff, daycare), and persons working in food and agriculture, manufacturing, corrections, the U.S. Postal Service, and grocery stores.
In considering the age groups to include in each phase, ACIP noted that persons age 75 years and older comprise 8% of the U.S. population, but account for 25% of the country’s COVID-19 deaths.
In making these recommendations, ACIP members emphasized their efforts to balance the goals of preventing morbidity and mortality due to SARS-CoV-2 infection with the goal of preserving societal function. In addition, the group wished to provide a framework for decisions while allowing flexibility for state and local governments to prioritize their vaccine allocations based on priorities that might vary based on local circumstances.
At the outset of the meeting, Nancy Messonnier, MD, director of the National Center for Immunization and Respiratory Diseases, CDC, put the deliberations in context by noting that current projections suggest vaccine would be available to vaccinate 20 million people in December, another 30 million in January, and another 50 million in February. Although CDC and ACIP strongly support all persons in the U.S. being vaccinated, it is recognized that prioritization will be necessary until vaccine supplies are ample.
Read the The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine—United States, December 2020 ([link removed]).
------------------------------------------------------------
CDC UPDATES WEB PAGES FEATURING PRACTICAL MATERIALS FOR ADMINISTRATION, STORAGE, AND HANDLING OF EACH AUTHORIZED COVID-19 VACCINE
CDC has refreshed its gateway pages leading to multiple practical web pages for each of the COVID-19 vaccines authorized for distribution in the United States. From the CDC’s COVID-19 Vaccination ([link removed]) gateway page, viewers can seek information for either the Pfizer-BioNTech COVID-19 vaccine ([link removed]) or the Moderna COVID-19 vaccine ([link removed]).
The following resources pertain to both mRNA vaccines:
* CDC's Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines ([link removed])
* CDC's U.S. COVID-19 Vaccine Product Information ([link removed])
Pfizer-BioNTech COVID-19 Vaccine Resources
Scrolling down the Pfizer-BioNTech COVID-19 Vaccine ([link removed]) gateway page, one finds information within the page plus links to useful PDF documents:
* Administration Overview: how to thaw, prepare ([link removed]), dilute ([link removed]), and administer, plus standing orders ([link removed]) and a screening form for contraindications and precautions ([link removed])
* Storage and Handling Overview: summary ([link removed]), beyond-use dating and labels ([link removed]) , a delivery checklist ([link removed]), storage and handling labels ([link removed]), expiration date tracking tool ([link removed]), ultra-cold storage logger (Fahrenheit ([link removed]) or Celsius ([link removed]), and dry ice safety
([link removed])
* CDC’s Pfizer-BioNTech COVID-19 Vaccine FAQs ([link removed])
[link removed]
Moderna COVID-19 Vaccine Resources
Scrolling down the Moderna COVID-19 vaccine ([link removed]) gateway page, one finds similar information and useful PDF documents:
* Administration Overview: preparation and administration summary ([link removed]) and standing orders ([link removed])
* Storage and Handling Overview: summary ([link removed]), beyond-use dating and labels ([link removed]), storage and handling labels ([link removed]), ultra-cold storage logger (Fahrenheit ([link removed]) or Celsius ([link removed])
* CDC’s Moderna COVID-19 Vaccine FAQs ([link removed])
[link removed]
Related Links:
* CDC's Vaccine Storage and Handling Toolkit ([link removed]) gateway page
* CDC's Vaccine Storage and Handling Toolkit ([link removed]) (PDF)
* FDA's COVID-19 Vaccines ([link removed]) gateway page
* CDC’s COVID-19 Vaccination ([link removed]) gateway page for healthcare professionals
* CDC's COVID-19 Vaccine Information for the Public ([link removed]) gateway page
* CMS information on Payment and CPT Code Structure for COVID-19 Vaccines ([link removed])
* AMA information on CPT Codes, Administration Codes and NDC Numbers for COVID-19 Vaccines ([link removed])
------------------------------------------------------------
MMWR Recap: CDC publishes recommendations for COVID-19 vaccines and phased allocation: Moderna’s vaccine in December 20 Early Release and Pfizer-BioNTech’s vaccine on December 18
CDC recently published several articles about specific COVID-19 vaccines, phased allocation, and ethical principles. Here is a recap:
* ACIP recommendations for Moderna COVID-19 vaccine (MMWR Early Release, December 20, HTML format ([link removed]) or PDF format ([link removed]); anticipated for December 25 issue
* ACIP priorities for allocating subsequent supplies of COVID-19 vaccines, Phases 1b and 1c (MMWR Early Release, December 22, HTML format ([link removed]) or PDF format ([link removed]); anticipated for December 25 issue
* ACIP recommendations for Pfizer-BioNTech COVID-19 vaccine (MMWR, December 18, HTML format ([link removed]) or PDF format ([link removed])
* ACIP priorities for allocating initial supplies of COVID-19 vaccines, Phase 1a (MMWR, December 11, HTML format ([link removed]) or PDF format ([link removed])
------------------------------------------------------------
CDC ADDS MANY MORE READY-TO-USE MATERIALS TO ITS COVID-19 VACCINATION COMMUNICATION TOOLKIT FOR MEDICAL CENTERS, CLINICS, AND CLINICIANS
CDC has released ready-to-use materials to help earn confidence about COVID-19 vaccination. CDC’s COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians ([link removed]) includes:
* A guide for building vaccine confidence ([link removed]) within health systems, medical offices, and clinics
* Communications and Confidence Readiness Checklist ([link removed])
* COVID-19 Vaccine Confidence Conversation Starter ([link removed])
* Turn-key slide decks for immunization coordinators, the healthcare team, and other healthcare personnel with information about COVID-19 vaccines, tips for building vaccine confidence, and tips for having effective vaccine conversations with patients
* Posters to download, print, and hang in your health facility
* Fact sheets and FAQs
* Social media sample messages
* Printable buttons/stickers for staff to wear after vaccination
* A video describing how ACIP makes recommendations and advises CDC on the use of vaccines in our country
View CDC’s COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians ([link removed]) today!
------------------------------------------------------------
Becker's Hospital Review publishes "Influenza Vaccination Remains a Priority Even as We Begin Rolling Out a COVID-19 Vaccination Program" by IAC authors—find it on IAC’s mass-vaccination-resources.org website
On December 9, Becker's Hospital Review published Influenza Vaccination Remains a Priority Even as We Begin Rolling Out a COVID-19 Vaccination Program ([link removed]), written by IAC's Drs. Carolyn Bridges and L.J Tan. A portion of the article is reprinted below.
...The risk of influenza disease is still present, and we must continue to seek innovative ways to provide convenient and safe access to influenza vaccination. This includes the use of drive-through influenza vaccination clinics, curbside clinics, parking lot clinics, and other similar interventions. Best practices for implementing mass immunization clinics are documented on the Immunization Action Coalition’s new website “Resources for Developing Mass Vaccination Clinics.” Efforts in innovating new and broad access points for influenza vaccination will serve to prepare us for the large-scale roll out of COVID-19 vaccine in phase 2 of the United States’ COVID-19 vaccination program.
Related Links
* IAC's Mass Vaccination Clinics: Challenges and Best Practices ([link removed]) archived webinar
* IAC's Mass Vaccination Resources ([link removed]) website
* CDC’s Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations ([link removed])
------------------------------------------------------------
VOICES FOR VACCINES RELEASES NEW PODCAST, "DR. OFFIT TALKS COVID-19 VACCINES," WITH ANSWERS TO COMMON COVID-19 QUESTIONS
Voices for Vaccines (VFV) has posted a new entry in its Vax Talk podcast series: Dr. Offit Talks COVID-19 Vaccines ([link removed]). A description from their web page is reprinted below.
Everyone we know has said, “If Paul Offit says it’s safe to get the vaccine, I will get it.” So, we had him on our podcast and asked him that and so much more.
* Visit VFV website podcast page ([link removed])
* Subscribe to Vax Talk via Apple Podcasts ([link removed]) or PodBean ([link removed])
Voices for Vaccines is a national organization of parents and others who are dedicated to raising the level of the voices of immunization supporters. VFV invites everyone who values vaccines to become a member, use VFV tools in their own community, and sign up for VFV’s free newsletter ([link removed]). Please spread the word to your friends and colleagues to join VFV!
Related Links
* Voices for Vaccines ([link removed]) website
* Voices for Vaccines Tools ([link removed]) gateway page
* JoinVoices for Vaccines ([link removed]) and receive weekly email updates
* FollowVoices for Vaccines on Facebook ([link removed])
------------------------------------------------------------
HRSA ANNOUNCES COMPETITION, WITH UP TO 70 CASH PRIZES TOTALING $1 MILLION, TO ADDRESS DECLINING VACCINATION COVERAGE AND WELL-CHILD VISITS
The Maternal and Child Health Bureau ([link removed]) (MCHB) of the Health Resources & Services Administration (HRSA) launched the Promoting Pediatric Primary Prevention (P4) Challenge ([link removed]) competition to respond to declining rates of childhood vaccination coverage ([link removed]) and well-child visits due to the COVID-19 pandemic. CDC data show that these declines may leave young children and communities vulnerable to vaccine-preventable diseases such as measles.
The P4 Challenge will award a total of $1 million in prizes for innovative approaches to increase access to and utilization of well-child visits and/or vaccination services within primary care settings. Partnerships with state and local organizations are encouraged. Submissions must include a primary care provider who delivers health services to children.
MCHB expects to select up to 50 Phase 1 winners and up to 20 Phase 2 winners. Proposals may be submitted between January 19 and March 15, 2021. Visit the P4 Challenge ([link removed]) website for more information.
------------------------------------------------------------
IAC EXPERTS CALLED ON BY NEWS MEDIA
With vaccines in the news so much lately, journalists have sought out IAC experts to communicate the intricacies of running a quality vaccination program. Our insights helped explain vaccines to the public and policy makers. We want to help everyone understand the complex work vaccinators do. We've reached mass markets and local stations, across the U.S. and overseas, via print, radio, television, blogs, and more. Here is a selection of our recent citations:
* Inspired Traveler: The Government Looks to Pharmacists to Increase Childhood Immunization ([link removed]) (12/17/20)
* KAKE: The Coronavirus Vaccine Rollout Will Be Messy. People Will Have to Deal with That ([link removed]) (12/14/20)
* New York Times: From Voter Fraud to Vaccine Lies: Misinformation Peddlers Shift Gears ([link removed]) (12/16/20)
* USA Today: Coronavirus Live Updates: Trump Says First Pfizer Vaccines Will Be Administered ‘In Less than 24 Hours’ ([link removed]) (12/11/20)
* Washington Times: Britain Begins First COVID-19 Vaccinations, Hopes to Provide Answers to Shot’s Biggest Questions ([link removed]) (12/7/20)
Related Link
* IAC in the News ([link removed]) gateway page
------------------------------------------------------------
NOT-TO-MISS IMMUNIZATION ARTICLES IN THE NEWS
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* NPR: Some Vials of COVID-19 Vaccine Contain Extra Doses, Expanding Supply, FDA Says ([link removed]) (12/16/20)
* New York Times: The Next Vaccine Challenge Is to Reassure Older Americans ([link removed]) (12/15/20)
* New York Times: ‘A Shot of Hope’: What the Vaccine Is like for Frontline Doctors and Nurses ([link removed]) (12/14/20)
* New York Times: ‘I Trust Science,’ Says Nurse Who Is First to Get Vaccine in U.S. ([link removed]) (12/14/20)
* Baltimore Sun: Maryland One of Several States with a Hepatitis A Outbreak; 190 Hospitalized This Year ([link removed]) (12/15/20)
* Kaiser Family Foundation: Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines ([link removed]) (12/14/20)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
IN IAC’S “VIDEO OF THE WEEK,” THE ALLIANCE FOR AGING RESEARCH ACKNOWLEDGES PANDEMIC STRESS AND THE IMPORTANCE OF GETTING VACCINATED AGAINST COVID-19
In this 1-minute video, the Alliance for Aging Research ([link removed]) shares how stressful this pandemic has been for all of us. When a vaccine becomes available, it will be important that we get vaccinated. Our Best Shot—Vaccine PSA ([link removed]) reminds viewers that, in the meantime, it is important for everyone to stay up to date on all vaccines, including flu and, for some people, pneumonia vaccines as well.
Visit the VOTW archive ([link removed]).
------------------------------------------------------------
Journal Articles and Newsletters
------------------------------------------------------------
CHOP's Vaccine Education Center publishes December issue of Vaccine Update newsletter
The Vaccine Education Center (VEC) ([link removed]) at Children's Hospital of Philadelphia (CHOP) publishes a monthly immunization-focused newsletter titled Vaccine Update. The December issue ([link removed]) includes the following articles:
* Three Questions You Will Get About the New mRNA Vaccines ([link removed]) by Charlotte A. Moser, BS, and Paul A. Offit, MD
* COVID-19 Vaccines and Allergic Reactions ([link removed]) by Paul A. Offit, MD
Additional resources, including information booklets for patients, are available in the full newsletter ([link removed]).
Access the sign-up form ([link removed]) to subscribe to Vaccine Update.
------------------------------------------------------------
On the Lighter Side
------------------------------------------------------------
Watch this vintage PSA about IAC Express from 2006, created by CDC and aired many times on CDC’s “Immunization Update” satellite broadcasts
Take a nostalgic look back at IAC Express in this 14-year-old public service announcement (PSA) produced for CDC’s “Immunization Update” satellite broadcasts by vaccine expert William L. Atkinson, MD, MPH, and CDC’s audio/visual team. The PSA aired many times in those years—some of you may remember it. This is part of a PSA collection curated by Dr. Atkinson.
[link removed]
Previous PSAs featured in “On the Lighter Side” are available when viewing this Vimeo video ([link removed]).
[link removed]
IAC Express
IAC Express Home ([link removed])
2020 Issues ([link removed])
2019 Issues ([link removed])
2018 Issues ([link removed])
2017 ([link removed]) – 1997 Issues ([link removed])
[link removed]
[link removed]
------------------------------------------------------------
Video of the Week
[link removed]
Our Best Shot—Vaccine PSA: In this 1-minute video, the Alliance for Aging Research shares how stressful this pandemic has been for all of us. When a vaccine becomes available, it will be important that we get vaccinated. This PSA reminds us that in the meantime, it is important for everyone to stay up to date on all vaccines, including flu and, if you are older, pneumonia vaccines as well.
Visit the VOTW archive ([link removed])
------------------------------------------------------------
[link removed]
[link removed]
------------------------------------------------------------
Follow Us
[link removed]
[link removed]
------------------------------------------------------------
Technically Speaking
[link removed]
Read Dr. Wexler's column for the Vaccine Education Center's monthly newsletter, Vaccine Update
------------------------------------------------------------
[link removed]
[link removed]
------------------------------------------------------------
Vaccinating Adults:
A Step-by-Step Guide
[link removed]
New! IAC's 142-page book available for free download ([link removed]).
------------------------------------------------------------
Calendar of Events
[link removed]
Conferences, meetings, and training opportunities
------------------------------------------------------------
Patient Record Cards
[link removed]
Record cards for patients --child & teen ([link removed]), adult ([link removed]), and lifetime ([link removed]) -- are printed on durable paper and sized to fit in a wallet when folded
------------------------------------------------------------
DVD: Immunization Techniques
[link removed]
Every practice should have this award winning, "how-to" training video
------------------------------------------------------------
Protect Newborns Guidebook
[link removed]
Comprehensive guide Hepatitis B: What Hospitals Need to Do to Protect Newborns ([link removed])
------------------------------------------------------------
Editorial Information
Editor
Deborah L. Wexler, MD ([email protected])
Associate Editors
John Grabenstein, RPh, PhD ([email protected])
Sharon Humiston, MD, MPH ([email protected])
Consulting Editors
Taryn Chapman, MS ([email protected])
Marian Deegan, JD ([email protected])
Courtnay Londo, MA ([email protected])
Technical Editor
Liv Augusta Anderson, MPP ([email protected])
About IAC Express
The Immunization Action Coalition welcomes redistribution of this issue of IAC Express or selected articles. When you do so, please add a note that the Immunization Action Coalition is the source of the material and provide a link to this issue ([link removed]).
IAC Express is supported in part by Grant No. 6NH23IP922550 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of IAC and do not necessarily represent the official views of CDC.
IAC Express Disclaimer ([link removed])
ISSN: 1526-1786
Our mailing address:
2550 University Avenue West, Suite 415 North
Saint Paul, MN 55114
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
Issue 1,541: December 23, 2020
Top Stories
* Happy holidays from all of us at IAC! We'll be back on January 6, 2021
* FDA issues EUA for Moderna mRNA vaccine after advisory committee vote; fact sheets published
* ACIP recommends second COVID-19 vaccine for use in U.S.; IAC summarizes December 19 meeting and highlights clinical considerations for use of mRNA vaccines
* ACIP provides interim recommendation for people who will be in Phases 1b and 1c of COVID-19 vaccination priority groups in the United States
* CDC updates web pages featuring practical materials for administration, storage, and handling of each authorized COVID-19 vaccine
* MMWR Recap: CDC publishes recommendations for COVID-19 vaccines and phased allocation: Moderna’s vaccine in December 20 Early Release and Pfizer-BioTech’s vaccine on December 18
* CDC adds many more ready-to-use materials to its COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians
* Becker's Hospital Review publishes "Influenza Vaccination Remains a Priority Even as We Begin Rolling Out a COVID-19 Vaccination Program" by IAC authors—find it on IAC’s mass-vaccination-resources.org website
* Voices for Vaccines releases new podcast, "Dr. Offit Talks COVID-19 Vaccines," with answers to common COVID-19 questions
* HRSA announces competition, with up to 70 cash prizes totaling $1 million, to address declining vaccination coverage and well-child visits
* IAC experts called on by news media
* Not-to-miss immunization articles in the news
Featured Resources
* In IAC’s “Video of the Week,” the Alliance for Aging Research acknowledges pandemic stress and the importance of getting vaccinated against COVID-19
Journal Articles and Newsletters
* CHOP's Vaccine Education Center publishes December issue of Vaccine Update newsletter
On the Lighter Side
* Watch this vintage PSA about IAC Express from 2006, created by CDC and aired many times on CDC’s “Immunization Update” satellite broadcasts
------------------------------------------------------------
Top Stories
------------------------------------------------------------
HAPPY HOLIDAYS FROM ALL OF US AT IAC! WE'LL BE BACK ON JANUARY 6, 2021
All of us at the Immunization Action Coalition (IAC) wish you, our readers, a safe, happy, and healthy remainder of the holiday season. We do not plan to publish another issue of IAC Express until January 6, 2021. But we will stay alert in these turbulent times and will publish a special edition, if warranted.
The IAC office will be closed on December 24 and 25, as well as January 1.
Happy holidays!
Group photo taken pre-pandemic in February 2020.
------------------------------------------------------------
FDA ISSUES EUA FOR MODERNA MRNA VACCINE AFTER ADVISORY COMMITTEE VOTE; FACT SHEETS PUBLISHED
On December 18, the Food and Drug Administration (FDA) issued the second Emergency Use Authorization ([link removed]) (EUA) for a vaccine to help prevent COVID-19 caused by SARS-CoV-2 virus in people 18 years of age and older. The EUA allows the Moderna COVID-19 vaccine (also known as mRNA-1273) to be distributed in the United States.
FDA’s action aligns with the unanimous recommendation of its Vaccines and Related Biological Products Advisory Committee ([link removed]) (VRBPAC), which determined on December 17 that the totality of scientific evidence available to date indicates that the benefits of vaccination with the Moderna COVID-19 vaccine outweigh the risks for use in people 18 years or older.
Below appear links to technical and supportive documents related to Moderna’s vaccine and the EUA. Most relevant to vaccinators are the Fact Sheet for Potential Recipients and Caregivers ([link removed]) and the Fact Sheet for Vaccination Providers ([link removed]). That second 22-page document contains 7 pages of EUA information plus 15 pages of the product’s prescribing information.
Related Links
* FDA's Press Release: FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine ([link removed]) (12/18/20)
* Moderna COVID-19 Vaccine EUA Fact Sheet for Potential Recipients and Caregivers ([link removed]) (5 pages)
* Moderna COVID-19 Vaccine EUA Fact Sheet for Vaccination Providers ([link removed]) (22 pages)
* FDA’s Letter to Moderna Issuing EUA ([link removed])
* FDA’s COVID-19 Vaccines ([link removed]) gateway page
* FDA’s Emergency Use Authorization for Vaccines Explained ([link removed]) web page
* FDA’s documents from December 17 VRBPAC meeting ([link removed])
* FDA’s Vaccine Development 101 ([link removed])
* FDA's Vaccine Facts: The Path for a COVID-19 Vaccine from Research to EUA ([link removed])
* Examples of Moderna COVID-19 Vaccine package labeling ([link removed])
------------------------------------------------------------
ACIP RECOMMENDS SECOND COVID-19 VACCINE FOR USE IN U.S.; IAC SUMMARIZES DECEMBER 19 MEETING AND HIGHLIGHTS CLINICAL CONSIDERATIONS FOR USE OF MRNA VACCINES
On December 19 ([link removed]), the Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of the Moderna COVID-19 vaccine for persons 18 years of age and older in the United States. This vote followed issuance of the FDA’s Emergency Use Authorization ([link removed]) (EUA) for the vaccine on December 18 (see story above).
The ACIP recommendations and additional guidance for the vaccine’s use became official when they were adopted by CDC and published as ACIP’s Interim Recommendation for Use of Moderna COVID-19 Vaccine—U.S, December 2020 ([link removed]) in the Morbidity and Mortality Weekly Report (MMWR) Early Release issued on December 20 ([link removed]).
Prior to the vote, ACIP received an overview of the mRNA-1273 vaccine from Moderna representatives. The Committee also reviewed its Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach and assessed available vaccine information using its Evidence to Recommendation (EtR) framework.
ACIP also received an update on anaphylaxis incidents following receipt of the Pfizer-BioNTech mRNA vaccine in the United Kingdom and the United States. All cases occurred within several minutes and were promptly treated. The prescribing information for both the Pfizer-BioNTech and Moderna COVID-19 vaccines states that a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine is a contraindication to vaccination. While these anaphylactic occurrences have been rare, all vaccination sites should be prepared to respond appropriately. CDC has posted Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites ([link removed]) to assist facilities in being prepared to recognize, respond, and report anaphylaxis. The guidance recommends that persons with a history of anaphylaxis (due to any cause) be observed for 30 minutes following vaccination. The recommended observation period for other persons is 15 minutes. Vaccination sites should prioritize the training of staff to recognize the early signs of anaphylaxis. Clinic personnel may refer to the CDC guidance for details about preparation for, assessment, and management of anaphylaxis.
CDC has posted Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States ([link removed]). Because the Pfizer-BioNTech and Moderna COVID-19 vaccines are both based on a mRNA platform, the clinical considerations for both vaccines are similar and have been incorporated on a single web page. Where appropriate, the page also notes the differences in the clinical considerations for the two vaccines. Consult the full web page for important details in vaccine administration with either vaccine. The key differences between the two products are highlighted below.
* Authorized age groups (under the Emergency Use Authorizations [EUAs])
+ Pfizer-BioNTech: ages 16 years and older
+ Moderna: ages 18 years and older
* Administration: The mRNA COVID-19 vaccine series consists of two doses administered intramuscularly:
+ Pfizer-BioNTech (30 µg, 0.3 ml): three weeks (21 days) apart*
+ Moderna (100 µg, 0.5 ml): one month (28 days) apart*
*Second doses administered within a grace period of no more than 4 days from the recommended date for the second dose are considered valid. However, doses administered earlier do not need to be repeated. The second dose should be administered as close to the recommended interval as possible. However, there is no maximum interval between the first and second dose for either vaccine. Do not restart the vaccination series.
* Interchangeability of COVID-19 vaccine products: ACIP did not state a preference for use of either mRNA vaccine. But the vaccines are NOT interchangeable, and care should be taken to ensure the same vaccine is used for both doses. However, if different mRNA vaccines are inadvertently administered, no additional doses of either vaccine are recommended at this time.
CDC is updating the COVID-19 information on its web pages frequently, with several key resources listed below.
Related Links
* ACIP Presentation Slides: December 19–20, 2020 ([link removed]) meeting gateway page
* MMWR: ACIP’s Interim Recommendation for Use of Moderna COVID-19—U.S, December 2020 ([link removed] )
* CDC’s Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites ([link removed])
* CDC’s Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States ([link removed])
* CDC’s COVID-19 Vaccination ([link removed]) gateway page for healthcare professionals
* CDC's COVID-19 Vaccine Information for the Public ([link removed]) gateway page
* Moderna’s Fact Sheet for Vaccination Providers ([link removed]) (PDF)
* Moderna’s Fact Sheet for Recipients and Caregivers ([link removed]) (PDF)
------------------------------------------------------------
ACIP PROVIDES INTERIM RECOMMENDATION FOR PEOPLE WHO WILL BE IN PHASES 1B AND 1C OF COVID-19 VACCINATION PRIORITY GROUPS IN THE UNITED STATES
During its meeting on December 20, the Advisory Committee on Immunization Practices (ACIP) approved a recommendation designating persons to include in Phases 1b and 1c of COVID-19 vaccination efforts during times of limited vaccine availability. This decision was an update to ACIP’s previous recommendation to include healthcare workers and residents of long-term care facilities in Phase 1a ([link removed]).
Specifically, the interim recommendation includes the following populations:
* Phase 1b: persons age 75 years and older and frontline essential workers*
* Phase 1c: persons age 65–74 years, persons age 16–64 years with high-risk medical conditions, and other essential workers*
* “Frontline essential workers” include workers who are in sectors essential to the functioning of society and who are at substantially higher risk for exposure to SARS-CoV-2 virus. Occupations in this group include first responders (e.g., firefighters, police), education staff (e.g., teachers, support staff, daycare), and persons working in food and agriculture, manufacturing, corrections, the U.S. Postal Service, and grocery stores.
In considering the age groups to include in each phase, ACIP noted that persons age 75 years and older comprise 8% of the U.S. population, but account for 25% of the country’s COVID-19 deaths.
In making these recommendations, ACIP members emphasized their efforts to balance the goals of preventing morbidity and mortality due to SARS-CoV-2 infection with the goal of preserving societal function. In addition, the group wished to provide a framework for decisions while allowing flexibility for state and local governments to prioritize their vaccine allocations based on priorities that might vary based on local circumstances.
At the outset of the meeting, Nancy Messonnier, MD, director of the National Center for Immunization and Respiratory Diseases, CDC, put the deliberations in context by noting that current projections suggest vaccine would be available to vaccinate 20 million people in December, another 30 million in January, and another 50 million in February. Although CDC and ACIP strongly support all persons in the U.S. being vaccinated, it is recognized that prioritization will be necessary until vaccine supplies are ample.
Read the The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine—United States, December 2020 ([link removed]).
------------------------------------------------------------
CDC UPDATES WEB PAGES FEATURING PRACTICAL MATERIALS FOR ADMINISTRATION, STORAGE, AND HANDLING OF EACH AUTHORIZED COVID-19 VACCINE
CDC has refreshed its gateway pages leading to multiple practical web pages for each of the COVID-19 vaccines authorized for distribution in the United States. From the CDC’s COVID-19 Vaccination ([link removed]) gateway page, viewers can seek information for either the Pfizer-BioNTech COVID-19 vaccine ([link removed]) or the Moderna COVID-19 vaccine ([link removed]).
The following resources pertain to both mRNA vaccines:
* CDC's Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines ([link removed])
* CDC's U.S. COVID-19 Vaccine Product Information ([link removed])
Pfizer-BioNTech COVID-19 Vaccine Resources
Scrolling down the Pfizer-BioNTech COVID-19 Vaccine ([link removed]) gateway page, one finds information within the page plus links to useful PDF documents:
* Administration Overview: how to thaw, prepare ([link removed]), dilute ([link removed]), and administer, plus standing orders ([link removed]) and a screening form for contraindications and precautions ([link removed])
* Storage and Handling Overview: summary ([link removed]), beyond-use dating and labels ([link removed]) , a delivery checklist ([link removed]), storage and handling labels ([link removed]), expiration date tracking tool ([link removed]), ultra-cold storage logger (Fahrenheit ([link removed]) or Celsius ([link removed]), and dry ice safety
([link removed])
* CDC’s Pfizer-BioNTech COVID-19 Vaccine FAQs ([link removed])
[link removed]
Moderna COVID-19 Vaccine Resources
Scrolling down the Moderna COVID-19 vaccine ([link removed]) gateway page, one finds similar information and useful PDF documents:
* Administration Overview: preparation and administration summary ([link removed]) and standing orders ([link removed])
* Storage and Handling Overview: summary ([link removed]), beyond-use dating and labels ([link removed]), storage and handling labels ([link removed]), ultra-cold storage logger (Fahrenheit ([link removed]) or Celsius ([link removed])
* CDC’s Moderna COVID-19 Vaccine FAQs ([link removed])
[link removed]
Related Links:
* CDC's Vaccine Storage and Handling Toolkit ([link removed]) gateway page
* CDC's Vaccine Storage and Handling Toolkit ([link removed]) (PDF)
* FDA's COVID-19 Vaccines ([link removed]) gateway page
* CDC’s COVID-19 Vaccination ([link removed]) gateway page for healthcare professionals
* CDC's COVID-19 Vaccine Information for the Public ([link removed]) gateway page
* CMS information on Payment and CPT Code Structure for COVID-19 Vaccines ([link removed])
* AMA information on CPT Codes, Administration Codes and NDC Numbers for COVID-19 Vaccines ([link removed])
------------------------------------------------------------
MMWR Recap: CDC publishes recommendations for COVID-19 vaccines and phased allocation: Moderna’s vaccine in December 20 Early Release and Pfizer-BioNTech’s vaccine on December 18
CDC recently published several articles about specific COVID-19 vaccines, phased allocation, and ethical principles. Here is a recap:
* ACIP recommendations for Moderna COVID-19 vaccine (MMWR Early Release, December 20, HTML format ([link removed]) or PDF format ([link removed]); anticipated for December 25 issue
* ACIP priorities for allocating subsequent supplies of COVID-19 vaccines, Phases 1b and 1c (MMWR Early Release, December 22, HTML format ([link removed]) or PDF format ([link removed]); anticipated for December 25 issue
* ACIP recommendations for Pfizer-BioNTech COVID-19 vaccine (MMWR, December 18, HTML format ([link removed]) or PDF format ([link removed])
* ACIP priorities for allocating initial supplies of COVID-19 vaccines, Phase 1a (MMWR, December 11, HTML format ([link removed]) or PDF format ([link removed])
------------------------------------------------------------
CDC ADDS MANY MORE READY-TO-USE MATERIALS TO ITS COVID-19 VACCINATION COMMUNICATION TOOLKIT FOR MEDICAL CENTERS, CLINICS, AND CLINICIANS
CDC has released ready-to-use materials to help earn confidence about COVID-19 vaccination. CDC’s COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians ([link removed]) includes:
* A guide for building vaccine confidence ([link removed]) within health systems, medical offices, and clinics
* Communications and Confidence Readiness Checklist ([link removed])
* COVID-19 Vaccine Confidence Conversation Starter ([link removed])
* Turn-key slide decks for immunization coordinators, the healthcare team, and other healthcare personnel with information about COVID-19 vaccines, tips for building vaccine confidence, and tips for having effective vaccine conversations with patients
* Posters to download, print, and hang in your health facility
* Fact sheets and FAQs
* Social media sample messages
* Printable buttons/stickers for staff to wear after vaccination
* A video describing how ACIP makes recommendations and advises CDC on the use of vaccines in our country
View CDC’s COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians ([link removed]) today!
------------------------------------------------------------
Becker's Hospital Review publishes "Influenza Vaccination Remains a Priority Even as We Begin Rolling Out a COVID-19 Vaccination Program" by IAC authors—find it on IAC’s mass-vaccination-resources.org website
On December 9, Becker's Hospital Review published Influenza Vaccination Remains a Priority Even as We Begin Rolling Out a COVID-19 Vaccination Program ([link removed]), written by IAC's Drs. Carolyn Bridges and L.J Tan. A portion of the article is reprinted below.
...The risk of influenza disease is still present, and we must continue to seek innovative ways to provide convenient and safe access to influenza vaccination. This includes the use of drive-through influenza vaccination clinics, curbside clinics, parking lot clinics, and other similar interventions. Best practices for implementing mass immunization clinics are documented on the Immunization Action Coalition’s new website “Resources for Developing Mass Vaccination Clinics.” Efforts in innovating new and broad access points for influenza vaccination will serve to prepare us for the large-scale roll out of COVID-19 vaccine in phase 2 of the United States’ COVID-19 vaccination program.
Related Links
* IAC's Mass Vaccination Clinics: Challenges and Best Practices ([link removed]) archived webinar
* IAC's Mass Vaccination Resources ([link removed]) website
* CDC’s Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations ([link removed])
------------------------------------------------------------
VOICES FOR VACCINES RELEASES NEW PODCAST, "DR. OFFIT TALKS COVID-19 VACCINES," WITH ANSWERS TO COMMON COVID-19 QUESTIONS
Voices for Vaccines (VFV) has posted a new entry in its Vax Talk podcast series: Dr. Offit Talks COVID-19 Vaccines ([link removed]). A description from their web page is reprinted below.
Everyone we know has said, “If Paul Offit says it’s safe to get the vaccine, I will get it.” So, we had him on our podcast and asked him that and so much more.
* Visit VFV website podcast page ([link removed])
* Subscribe to Vax Talk via Apple Podcasts ([link removed]) or PodBean ([link removed])
Voices for Vaccines is a national organization of parents and others who are dedicated to raising the level of the voices of immunization supporters. VFV invites everyone who values vaccines to become a member, use VFV tools in their own community, and sign up for VFV’s free newsletter ([link removed]). Please spread the word to your friends and colleagues to join VFV!
Related Links
* Voices for Vaccines ([link removed]) website
* Voices for Vaccines Tools ([link removed]) gateway page
* JoinVoices for Vaccines ([link removed]) and receive weekly email updates
* FollowVoices for Vaccines on Facebook ([link removed])
------------------------------------------------------------
HRSA ANNOUNCES COMPETITION, WITH UP TO 70 CASH PRIZES TOTALING $1 MILLION, TO ADDRESS DECLINING VACCINATION COVERAGE AND WELL-CHILD VISITS
The Maternal and Child Health Bureau ([link removed]) (MCHB) of the Health Resources & Services Administration (HRSA) launched the Promoting Pediatric Primary Prevention (P4) Challenge ([link removed]) competition to respond to declining rates of childhood vaccination coverage ([link removed]) and well-child visits due to the COVID-19 pandemic. CDC data show that these declines may leave young children and communities vulnerable to vaccine-preventable diseases such as measles.
The P4 Challenge will award a total of $1 million in prizes for innovative approaches to increase access to and utilization of well-child visits and/or vaccination services within primary care settings. Partnerships with state and local organizations are encouraged. Submissions must include a primary care provider who delivers health services to children.
MCHB expects to select up to 50 Phase 1 winners and up to 20 Phase 2 winners. Proposals may be submitted between January 19 and March 15, 2021. Visit the P4 Challenge ([link removed]) website for more information.
------------------------------------------------------------
IAC EXPERTS CALLED ON BY NEWS MEDIA
With vaccines in the news so much lately, journalists have sought out IAC experts to communicate the intricacies of running a quality vaccination program. Our insights helped explain vaccines to the public and policy makers. We want to help everyone understand the complex work vaccinators do. We've reached mass markets and local stations, across the U.S. and overseas, via print, radio, television, blogs, and more. Here is a selection of our recent citations:
* Inspired Traveler: The Government Looks to Pharmacists to Increase Childhood Immunization ([link removed]) (12/17/20)
* KAKE: The Coronavirus Vaccine Rollout Will Be Messy. People Will Have to Deal with That ([link removed]) (12/14/20)
* New York Times: From Voter Fraud to Vaccine Lies: Misinformation Peddlers Shift Gears ([link removed]) (12/16/20)
* USA Today: Coronavirus Live Updates: Trump Says First Pfizer Vaccines Will Be Administered ‘In Less than 24 Hours’ ([link removed]) (12/11/20)
* Washington Times: Britain Begins First COVID-19 Vaccinations, Hopes to Provide Answers to Shot’s Biggest Questions ([link removed]) (12/7/20)
Related Link
* IAC in the News ([link removed]) gateway page
------------------------------------------------------------
NOT-TO-MISS IMMUNIZATION ARTICLES IN THE NEWS
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* NPR: Some Vials of COVID-19 Vaccine Contain Extra Doses, Expanding Supply, FDA Says ([link removed]) (12/16/20)
* New York Times: The Next Vaccine Challenge Is to Reassure Older Americans ([link removed]) (12/15/20)
* New York Times: ‘A Shot of Hope’: What the Vaccine Is like for Frontline Doctors and Nurses ([link removed]) (12/14/20)
* New York Times: ‘I Trust Science,’ Says Nurse Who Is First to Get Vaccine in U.S. ([link removed]) (12/14/20)
* Baltimore Sun: Maryland One of Several States with a Hepatitis A Outbreak; 190 Hospitalized This Year ([link removed]) (12/15/20)
* Kaiser Family Foundation: Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines ([link removed]) (12/14/20)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
IN IAC’S “VIDEO OF THE WEEK,” THE ALLIANCE FOR AGING RESEARCH ACKNOWLEDGES PANDEMIC STRESS AND THE IMPORTANCE OF GETTING VACCINATED AGAINST COVID-19
In this 1-minute video, the Alliance for Aging Research ([link removed]) shares how stressful this pandemic has been for all of us. When a vaccine becomes available, it will be important that we get vaccinated. Our Best Shot—Vaccine PSA ([link removed]) reminds viewers that, in the meantime, it is important for everyone to stay up to date on all vaccines, including flu and, for some people, pneumonia vaccines as well.
Visit the VOTW archive ([link removed]).
------------------------------------------------------------
Journal Articles and Newsletters
------------------------------------------------------------
CHOP's Vaccine Education Center publishes December issue of Vaccine Update newsletter
The Vaccine Education Center (VEC) ([link removed]) at Children's Hospital of Philadelphia (CHOP) publishes a monthly immunization-focused newsletter titled Vaccine Update. The December issue ([link removed]) includes the following articles:
* Three Questions You Will Get About the New mRNA Vaccines ([link removed]) by Charlotte A. Moser, BS, and Paul A. Offit, MD
* COVID-19 Vaccines and Allergic Reactions ([link removed]) by Paul A. Offit, MD
Additional resources, including information booklets for patients, are available in the full newsletter ([link removed]).
Access the sign-up form ([link removed]) to subscribe to Vaccine Update.
------------------------------------------------------------
On the Lighter Side
------------------------------------------------------------
Watch this vintage PSA about IAC Express from 2006, created by CDC and aired many times on CDC’s “Immunization Update” satellite broadcasts
Take a nostalgic look back at IAC Express in this 14-year-old public service announcement (PSA) produced for CDC’s “Immunization Update” satellite broadcasts by vaccine expert William L. Atkinson, MD, MPH, and CDC’s audio/visual team. The PSA aired many times in those years—some of you may remember it. This is part of a PSA collection curated by Dr. Atkinson.
[link removed]
Previous PSAs featured in “On the Lighter Side” are available when viewing this Vimeo video ([link removed]).
[link removed]
IAC Express
IAC Express Home ([link removed])
2020 Issues ([link removed])
2019 Issues ([link removed])
2018 Issues ([link removed])
2017 ([link removed]) – 1997 Issues ([link removed])
[link removed]
[link removed]
------------------------------------------------------------
Video of the Week
[link removed]
Our Best Shot—Vaccine PSA: In this 1-minute video, the Alliance for Aging Research shares how stressful this pandemic has been for all of us. When a vaccine becomes available, it will be important that we get vaccinated. This PSA reminds us that in the meantime, it is important for everyone to stay up to date on all vaccines, including flu and, if you are older, pneumonia vaccines as well.
Visit the VOTW archive ([link removed])
------------------------------------------------------------
[link removed]
[link removed]
------------------------------------------------------------
Follow Us
[link removed]
[link removed]
------------------------------------------------------------
Technically Speaking
[link removed]
Read Dr. Wexler's column for the Vaccine Education Center's monthly newsletter, Vaccine Update
------------------------------------------------------------
[link removed]
[link removed]
------------------------------------------------------------
Vaccinating Adults:
A Step-by-Step Guide
[link removed]
New! IAC's 142-page book available for free download ([link removed]).
------------------------------------------------------------
Calendar of Events
[link removed]
Conferences, meetings, and training opportunities
------------------------------------------------------------
Patient Record Cards
[link removed]
Record cards for patients --child & teen ([link removed]), adult ([link removed]), and lifetime ([link removed]) -- are printed on durable paper and sized to fit in a wallet when folded
------------------------------------------------------------
DVD: Immunization Techniques
[link removed]
Every practice should have this award winning, "how-to" training video
------------------------------------------------------------
Protect Newborns Guidebook
[link removed]
Comprehensive guide Hepatitis B: What Hospitals Need to Do to Protect Newborns ([link removed])
------------------------------------------------------------
Editorial Information
Editor
Deborah L. Wexler, MD ([email protected])
Associate Editors
John Grabenstein, RPh, PhD ([email protected])
Sharon Humiston, MD, MPH ([email protected])
Consulting Editors
Taryn Chapman, MS ([email protected])
Marian Deegan, JD ([email protected])
Courtnay Londo, MA ([email protected])
Technical Editor
Liv Augusta Anderson, MPP ([email protected])
About IAC Express
The Immunization Action Coalition welcomes redistribution of this issue of IAC Express or selected articles. When you do so, please add a note that the Immunization Action Coalition is the source of the material and provide a link to this issue ([link removed]).
IAC Express is supported in part by Grant No. 6NH23IP922550 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of IAC and do not necessarily represent the official views of CDC.
IAC Express Disclaimer ([link removed])
ISSN: 1526-1786
Our mailing address:
2550 University Avenue West, Suite 415 North
Saint Paul, MN 55114
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp